Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Neoplasms × donafenib × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 15 Differentiated Thyroid Cancer 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Solid Tumor 1 Recurrence 1 Pancreatic Neoplasms 1 Locally Advanced Thyroid Gland Carcinoma 1 Liver Neoplasms 1 Leukemia, Myeloid, Acute 1 Esophageal Neoplasms 1 Cirrhosis, Familial, with Pulmonary Hypertension 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Biliary Tract Carcinoma 1 Biliary Tract Adenocarcinoma 1 Biliary Malignant Tumors 1 Advanced Solid Tumor 1

Interventions

Sorafenib 59 Bevacizumab 35 Oxaliplatin 22 Doxorubicin 19 Fluorouracil 18 Nivolumab 17 Gemcitabine 17 Radiosurgery 16 pembrolizumab 15 lenvatinib 15 Cisplatin 15 durvalumab 14 Radiofrequency Ablation 14 Capecitabine 14 atezolizumab 12 Leucovorin 12 Hepatectomy 12 Radiotherapy 10 Irinotecan 10 Cyclophosphamide 10 Blood Specimen Collection 9 tremelimumab 8 Liver Transplantation 8 Drug Therapy 8 Chemotherapy, Adjuvant 8 Carboplatin 8 fludarabine 7 Melphalan 7 Ipilimumab 7 Everolimus 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05713994 2025-03-25

CCGLC-001

Tongji Hospital

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡